Two large steps forward, one small step back

被引:0
|
作者
Marcus-Alexander Wörns
Peter R. Galle
机构
[1] University Medical Centre of the Johannes Gutenberg-University,Department of Internal Medicine I and the Cirrhosis Centre Mainz (CCM)
关键词
D O I
暂无
中图分类号
学科分类号
摘要
In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.
引用
下载
收藏
页码:74 / 76
页数:2
相关论文
共 50 条